Pyxis Oncology (PYXS) Accumulated Expenses (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Accumulated Expenses data on file, last reported at $3.3 million in Q4 2025.

• Accumulated Expenses for Q4 2025 came in at $3.3 million, down 70.84% year-over-year; the trailing twelve-month figure through Dec 2025 was $3.3 million (down 70.84% YoY), and the FY2025 annual result was $3.3 million, down 70.84% from the prior year.
• Accumulated Expenses declined to $3.3 million in Q4 2025 per PYXS's latest filing, from $8.0 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $17.1 million in Q1 2022 and troughed at $3.3 million in Q4 2025.
• A 5-year average of $9.5 million and a median of $9.0 million in 2025 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2021 and 2025: Accumulated Expenses jumped 230.1% in 2021, then plunged 70.84% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $6.6 million in 2021, then tumbled by 35.71% to $4.2 million in 2022, then surged by 206.06% to $13.0 million in 2023, then fell by 12.34% to $11.4 million in 2024, then sank by 70.84% to $3.3 million in 2025.
• Business Quant data shows PYXS's Accumulated Expenses at $3.3 million in Q4 2025, $8.0 million in Q3 2025, and $6.7 million in Q2 2025.